Clay Siegall Dedication to Alleviate Suffering for Cancer Patients
Seattle Genetics is one of the numerous companies that have been making numerous advances and innovations in the field of cancer research. Dr. Clay Siegall co-founder and the current CEO, President, as well as the Chairperson of the board of Seattle Genetics. Since he commenced his career in biomedical studies two decades ago, he has been enthusiastic to alleviate suffering for cancer patients.
Dr. Clay Siegall has been working very hard to ensure that his company attains great achievements in cancer research and especially getting the best therapies for cancer patients for the past one decade. He furthered his studies at George Washington University where he attained a Ph.D. in Genetics. He has numerous professional accomplishments. Dr. Siegall started his career at Bristol-Myers Squibb Pharmaceutical Research Institute where he was hired as the Senior Research Investigator. Before long, he was appointed to be the Principal Scientist and later on promoted to be a Staff Fellow as well as Biotechnology Fellow at the National Cancer Institute. After the promotion, he started working on launching the Seattle Genetics.
Dr. Siegall has been diligent about coming up with top-notch developments. He is motivated by his desire to assist people and eliminate their suffering. The accomplishments of his organization can be attributed to his passion and drive. Under his leadership, Seattle Genetics released the first ADCs (antibody-drug conjugates) which acquired FDA approval in 2011. ADCETRIS, an example of the ADCs has touched the lives of many in more than 60 countries.
According to Seattle Times, Seattle Genetics is looking forward to being at the front line of battling cancer. It is the among the largest biotech companies in the world. It has 800 employees and is looking forward to increasing the figure to 1000. Investors gave the company more than 50% last year. The company is famous for its ADCETRIS drug which treats the Hodgkin Lymphoma.
Dr. Siegall has displayed exemplary leadership qualities especially during the fundraising that raised more than $1.2 billion to fund Seattle Genetics. These funds have helped Seattle Genetics to advance cancer treatments with the most advanced technology. Dr. Siegall has not shown any signs of resigning from the medical industry. Currently, he has 15 patents. Clay Siegall has published more than 70 publications on new research methods as well as discoveries.